AstraZeneca's earnings call presented a strong performance with significant revenue and EPS growth, driven by robust demand across oncology and biopharmaceuticals. The company achieved numerous regulatory approvals and positive clinical trial results, indicating a successful pipeline and future growth potential. However, challenges such as the impact of Medicare Part D redesign, Soliris biosimilar competition, and growth rate issues in China were noted. Overall, the positive highlights outweigh the challenges, suggesting a promising outlook.

Company Guidance -

Q3 2025

During AstraZeneca's H1 and Q2 2025 investor call, the company provided several key metrics indicating strong performance and future growth prospects. Total revenue grew by 11% in the first half of the year, driven by a 10% increase in product sales and a 38% rise in alliance revenue. The company reported a core EPS growth of 17% and a gross margin of 83%, reflecting favorable sales mix and exchange rates. AstraZeneca achieved 19 regulatory approvals across key regions and announced positive results from 12 Phase III trials, including five new molecular entities. Oncology and biopharmaceuticals saw double-digit growth, with rare diseases returning to a 7% growth in Q2. The company reiterated its guidance for a high single-digit percentage increase in revenue and a low double-digit percentage increase in EPS for the year. Significant investment continues in R&D, with costs representing 23% of total revenue, supported by a robust pipeline poised to generate over $10 billion in peak year revenue on a risk-adjusted basis. The company remains confident in achieving its $80 billion revenue target by 2030.

Strong Revenue and Core EPS Growth

Total revenue grew by 11% in the first half of 2025, driven by demand for innovative medicines. Core EPS increased by 17%.

Regulatory Approvals and Pipeline Success

Achieved 19 regulatory approvals in key regions. Announced results of 12 positive Phase III trials, including pivotal data for 5 new molecular entities.

Oncology and Biopharmaceuticals Growth

Double-digit growth in oncology and biopharmaceuticals. Rare disease business returned to growth with a 7% increase in the second quarter.

Positive Trial Results in Oncology

Positive results for camizestrant in SERENA-6, Enhertu in DESTINY-Breast09 and DESTINY-Breast11, and Tagrisso in FLAURA2 trial.

Successful Launches and New Indications

Strong launches for new Imfinzi regimens and continued momentum in established lung and liver indications. Enhertu revenues grew by 42%.

Record Patient Recruitment in Clinical Trials

Over 56,000 patients recruited in clinical trials by the end of Q2 2025. More than 50% of trials recruiting ahead of plan.

Continued Investment in R&D and Transformative Technologies

Significant investments in R&D and transformative technologies, including IO bispecifics and ADCs.

AstraZeneca (AZN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AZN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	1.14 / -	1.04	―	―	―
Jul 29, 2025	2025 (Q2)	1.07 / 1.08	0.99	9.60% (+0.09)
Apr 29, 2025	2025 (Q1)	1.12 / 1.25	1.03	20.87% (+0.22)
Feb 06, 2025	2024 (Q4)	1.03 / 1.04	0.725	44.14% (+0.32)
Nov 12, 2024	2024 (Q3)	1.02 / 1.04	0.865	20.23% (+0.18)
Jul 25, 2024	2024 (Q2)	0.98 / 0.99	1.075	-7.91% (-0.08)
Apr 25, 2024	2024 (Q1)	0.96 / 1.03	0.96	7.29% (+0.07)
Feb 08, 2024	2023 (Q4)	0.73 / 0.72	0.69	5.07% (+0.04)
Nov 09, 2023	2023 (Q3)	0.84 / 0.86	0.835	3.59% (+0.03)
Jul 28, 2023	2023 (Q2)	0.99 / 1.07	0.86	25.00% (+0.21)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AZN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$71.83	$73.98	+2.99%
Apr 29, 2025	$69.93	$71.71	+2.55%
Feb 06, 2025	$69.96	$71.36	+2.00%
Nov 12, 2024	$63.89	$64.29	+0.63%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.